ArticleNPJ dementia2026
Tau pathology reprograms glucose metabolism to support cortical hyperexcitability, excitatory/inhibitory imbalance, and sleep loss.
Article in NPJ dementia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Sleep Disturbance Correlates with Cognitive Impairment Partly via Plasma p-Tau217: ADNI Cross-Sectional Evidence and P301L Mouse Mechanistic Observations.International journal of molecular sciences · 2026Article
- Advancing a systems-level understanding of neurodegeneration: the BrightFocus Alzheimer's disease research portfolio.Molecular neurodegeneration · 2026Article
- Early microglial response to amyloid plaques drives sleep loss in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Dual orexin receptor antagonism with lemborexant enhances microglial clearance of β-amyloid in mice.Molecular neurodegeneration · 2026Article
- Lactate metabolism links reactive microglia, amyloid pathology, and Aβ dynamics.Journal of neuroinflammation · 2026Article
Corrections and comments
- Update of
Authors and funding
14 authors.
Funding
Abstract
Alzheimer's disease (AD) is not only defined by amyloid-β and tau pathology but by early metabolic disruptions and hyperexcitability. How tau independently reshapes the coupling of metabolism-excitability to impact processes like sleep remains unclear. Here, hyperphosphorylated tau preserves whole-body metabolic function while driving cortical hyperexcitability and sleep loss in mouse models of tauopathy. Tau pathology prevented age-related decline in glucose tolerance and maintained diurnal hippocampal interstitial fluid (ISF) glucose and lactate rhythms, which were lost in aging wildtype mice. Stable isotope-resolved metabolomics revealed that tau pathology preferentially shunts glucose toward glutamate synthesis at the expense of GABA, suggesting an excitatory/inhibitory (E/I) imbalance not explained by synaptic mitochondrial deficits but by glycolytic flux. Hallmarks of hyperexcitability and impaired inhibitory tone were confirmed by continuous EEG/EMG recordings where decreased beta power, reduced cortical coherence, a flatter aperiodic slope, and abnormal gamma oscillations were associated with NREM and REM sleep loss. Widefield optical imaging confirmed exaggerated glutamatergic calcium activity during whisker stimulation. Together, these findings show that tau pathology drives glucose-dependent hyperexcitability while impairing network synchrony and sleep/wake architecture. This work identifies E/I imbalance as a mechanistic link between tau, metabolism, and sleep loss, highlighting a therapeutic target for tauopathies like AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.